TRINETRA › Sectors › Healthcare
Divi's Laboratories Limited (DIVISLAB) — share price, P/E and fundamentals
Divi's Laboratories Limited (NSE: DIVISLAB) closed at ₹9,780.00 on 30 Oct 2026, +47.7% over one year, against a 52-week range of ₹5,647.50 – ₹9,865.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 1 Aug 2026) it reported revenue of ₹3,080 cr and net profit of ₹902 cr, a 29.3% net margin; revenue grew 27.8% and profit grew 61.0% year on year.
On four consecutive filed quarters its trailing P/E is 88.6; since 19 May 2025 its own P/E has ranged from 62.3 to 88.7 (median 76.3), and today's reading is higher than 100% of those 359 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 21.5%, ROCE 26.4%, debt-to-equity 0.00, Piotroski F-score 5 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 98% of 63 sector peers; PBT margin higher than 98% of 63 sector peers; ROE higher than 79% of 63 sector peers.
Key figures
| Last close | ₹9,780.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +1.9% / +53.7% / +47.7% |
| 52-week low – high | ₹5,647.50 – ₹9,865.00 |
| Market capitalisation | ₹2,59,170 cr |
| Trailing P/E | 88.6 |
| Price / book | 15.46 |
| EV / EBITDA | 59.6 |
| Earnings yield | 1.1% |
| TTM EPS | ₹110.38 |
| TTM net profit | ₹2,925 cr |
| Quarter revenue | ₹3,080 cr |
| Quarter net profit | ₹902 cr |
| Net margin | 29.3% |
| Revenue growth (YoY) | +27.8% |
| Profit growth (YoY) | +61.0% |
| Return on equity | 21.5% |
| ROCE | 26.4% |
| Debt / equity | 0.00 |
| Current ratio | 5.43 |
| Free cash flow | ₹218 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹444.6 cr |
Against Healthcare peers
| Metric | DIVISLAB | Peer median | Percentile |
|---|---|---|---|
| Net margin | 29.29 | 12.67 | 98 |
| PBT margin | 38.31 | 17.57 | 98 |
| ROE | 21.53 | 13.86 | 79 |
| ROCE | 26.37 | 16.59 | 83 |
| Debt / equity | 0.00 | 0.11 | 12 |
| Cash conversion | 1.07 | 1.25 | 38 |
| Trailing P/E | 88.61 | 43.07 | 92 |
| P/B | 15.46 | 5.88 | 89 |
Questions
What is the P/E ratio of Divi's Laboratories Limited?
Divi's Laboratories Limited's trailing P/E is 88.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 19 May 2025 its P/E has ranged 62.3–88.7.
What were Divi's Laboratories Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Divi's Laboratories Limited reported revenue of ₹3,080 cr and net profit of ₹902 cr (consolidated), filed with the exchange on 1 Aug 2026.
What is Divi's Laboratories Limited's ROE?
Return on equity is 21.5% based on the balance sheet dated 31 Mar 2026.
Does Divi's Laboratories Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.
What is DIVISLAB's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, DIVISLAB traded between ₹5,647.50 and ₹9,865.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.